patent.fyi
Applications  /  US 2026/0355152
United States Patent Application Publication

US 2026/0355152 A1

Published
Nov 12, 2026
Filed
Nov 21, 2023
Earliest date on the face
Dec 1, 2022
Classification
A61K 31/381
First published here
Nov 19, 2026

Generated automatically. Not reviewed by a person. Not legal advice or an opinion.

Section 1 · machine-generated

What if?

Questions about how individual parts of claim 1 might be changed. A question may describe something different from what the claim language recites, or a version of it; no view is offered on which.

1.1Self-supporting drug adhesive web

What ifWhat if a cohesive drug-in-adhesive sheet held its shape without a separate backing?
Claim language“a backing layer”

A crosslinked acrylic pressure-sensitive adhesive forms a free-standing sheet between two disposable release liners. Both liners are removed during application, and the crosslinked polymer provides cohesion during wear.

1.1Strap-retained membrane patch

What ifWhat if an adjustable elastic strap held a membrane patch against the skin?
Claim language“an adhesive agent layer”

A drug reservoir sits between an impermeable backing and a skin-facing, rate-controlling polymer membrane. An elastic strap maintains skin contact while dissolved rotigotine diffuses through the membrane.

1.2Tocopherol in the adhesive

What ifWhat if the adhesive contained alpha-tocopherol as its antioxidant?
Claim language“propyl gallate”

Alpha-tocopherol disperses in a hydrophobic pressure-sensitive adhesive during compounding. Its phenolic group donates hydrogen to peroxyl radicals and interrupts oxidative chain reactions in the matrix.

1.2Molded microcup skin attachment

What ifWhat if molded silicone microcups supplied skin attachment through suction?
Claim language“an adhesive base agent”

Pressing the cured elastomer against the skin deforms the cups and expels air. Elastic recovery lowers pressure inside the sealed cups, holding a central drug reservoir and its release membrane against the skin.

Section 2 · machine-generated

Variations

Further arrangements of the same subject matter, described here as of the publication date at the foot of this page.

Other field of use

Patch for membrane transport testing

A laboratory test coupon comprises a flexible backing and a pressure-sensitive adhesive layer containing rotigotine and propyl gallate. The adhesive face contacts a synthetic diffusion membrane clamped between the donor and receptor chambers of a diffusion cell, with the backing facing the donor chamber. Samples taken from the stirred receptor fluid at scheduled intervals provide the cumulative mass of rotigotine transported per unit membrane area.

Component substitution

Tocopherol in the adhesive matrix

Alpha-tocopherol replaces propyl gallate as the antioxidant in a pressure-sensitive adhesive layer containing rotigotine free base. The alpha-tocopherol and rotigotine are dissolved in a solvent compatible with the adhesive solution before the mixtures are combined. The resulting blend is coated onto a release liner and dried, and the exposed adhesive surface is laminated to a flexible backing film.

Parameter or scale variation

Three patch areas from one web

A continuous backing carries a uniform rotigotine and propyl gallate adhesive layer at a dry coat mass of 80 grams per square meter. The laminate is die-cut into rectangular patches with active dimensions of 20 by 25, 25 by 40, and 40 by 50 millimeters. These dimensions give nominal active areas of 5, 10, and 20 square centimeters and nominal adhesive masses of 40, 80, and 160 milligrams, respectively.

Combination with existing systems

Patch with a fixation overlay

A rotigotine and propyl gallate adhesive layer sits between the skin and a flexible patch backing. A separate polyurethane fixation film carries a skin-contact adhesive and extends 10 millimeters beyond the patch around its perimeter. The film adheres to the exposed backing at the center and to the surrounding skin at the perimeter, holding the patch edges against the skin during movement.

Nitrogen-flushed unit-dose pouch

Each patch comprises a flexible backing, a pressure-sensitive adhesive layer containing rotigotine and propyl gallate, and a removable liner over the adhesive face. A form-fill-seal machine places each lined patch in a pouch made from a polymer and aluminum foil laminate with an inner heat-seal layer. The filling station flushes the open pouch with nitrogen before sealing, and the foil layer limits oxygen and water vapor ingress during storage.

Automated or data-driven variant

Closed-loop dry coat mass control

A slot die coats a moving release liner with a pressure-sensitive adhesive solution containing rotigotine and propyl gallate. A scanning basis-weight gauge downstream of the drying oven measures the coated web, and a controller subtracts the measured basis weight of the uncoated liner to estimate dry coat mass per area. The controller compares the cross-web average with a setpoint and adjusts the metering pump speed using the web travel time between the die and gauge to associate measurements with coating adjustments. A downstream nip laminates the backing film onto the dried adhesive.

Specific version of a part

Separate drug reservoir and adhesive

A heat-sealed backing and polymer membrane enclose a semisolid reservoir containing rotigotine and propyl gallate. A pressure-sensitive adhesive ring surrounds the membrane, and rotigotine reaches the skin through the central membrane.

Polyester film backing

A 25-micrometer polyethylene terephthalate film supports the adhesive layer. Corona treatment of the adhesive-facing surface increases surface energy and improves anchorage between the film and adhesive.

Acrylic matrix with free base

Rotigotine free base and propyl gallate are mixed into a solvent-borne acrylic pressure-sensitive adhesive. The mixture is coated onto a release liner and dried before the backing film is laminated onto the adhesive.

Silicone matrix with propyl gallate

A silicone pressure-sensitive adhesive contains dispersed rotigotine free base and propyl gallate. The adhesive mixture is knife-coated onto a fluoropolymer-coated release liner, dried, and laminated to a flexible backing.

Section 3 · quoted from USPTO records

Other work

Passages reproduced word for word from two earlier-published U.S. patent documents, placed beside the language of claim 1. No characterization is offered. Each passage is marked A or B for the document it comes from; ¶ numbers are the paragraph numbers in the USPTO’s published full text of that document.

Document AUS 2012/0101146 A1
Published
Apr 26, 2012
Filed
Jun 24, 2010
Class
A61K 31/381
Document BUS 9,034,914 B2
Published
May 19, 2015
Filed
Mar 31, 2014
Class
A61K 31/381
Claim 1
Document A
Document B
1.1a backing layer and an adhesive agent layer
The TTS comprises a backing layer, inert with respect to the constituents of the matrix, a self-adhesive matrix layer containing an effective quantity of rotigotine or rotigotine hydrochloride and a protective film which is to be removed before use.
A · US 2012/0101146 A1 · ¶ 18
The US comprises a backing layer, inert with respect to the constituents of the matrix, a self-adhesive matrix layer containing an effective quantity of rotigotine or rotigotine hydrochloride and a protective film which is to be removed before use.
B · US 9,034,914 B2 · ¶ 19
1.2wherein the adhesive agent layer comprises an adhesive base agent, propyl gallate, and at least one selected from the group consisting of rotigotine and a pharmaceutically acceptable salt of rotigotine.
The TTS comprises a backing layer, inert with respect to the constituents of the matrix, a self-adhesive matrix layer containing an effective quantity of rotigotine or rotigotine hydrochloride and a protective film which is to be removed before use. The matrix system is composed of a non-aqueous polymer adhesive system, based on acrylate or silicone.
A · US 2012/0101146 A1 · ¶ 18
The US comprises a backing layer, inert with respect to the constituents of the matrix, a self-adhesive matrix layer containing an effective quantity of rotigotine or rotigotine hydrochloride and a protective film which is to be removed before use. The matrix system is composed of a non-aqueous polymer adhesive system, based on acrylate or silicone.
B · US 9,034,914 B2 · ¶ 19

An empty cell means only that no passage was reproduced there.

Statements in these documents
The present invention relates to new salts of 6-(propyl-(2-thiophen-2-ylethyl)amino)tetralin-1-ol (rotigotine), their use as a medicament, for example for the treatment of Parkinson Disease, RLS, fybromyalgia and/or depression, in particular through electromotive administration.
A · US 2012/0101146 A1 · ¶ 1
The formulations are further characterized by good to excellent solubility of the salts in aqueous solutions.
A · US 2012/0101146 A1 · ¶ 3
The present invention relates to new salts of 6-(propyl-(2-thiophen-2-ylethyl)amino)tetralin-1-ol(rotigotine), their use as a medicament, for example for the treatment of Parkinson Disease, RLS, fibromyalgia and/or depression, in particular through electromotive administration.
B · US 9,034,914 B2 · ¶ 2
The formulations are further characterized by good to excellent solubility of the salts in aqueous solutions.
B · US 9,034,914 B2 · ¶ 4
Cite aspatent.fyi, US 2026/0355152 A1, claim 1, first published 2026-11-19T08:28:42-05:00, https://patent.fyi/US20260355152/, SHA-256 04fc2666b875d6ef60bba5420a1e11369afba485b15cd36c81ad982042e39b88
First published
Permanent addresshttps://patent.fyi/US20260355152/
Content fingerprint (SHA-256)04fc2666b875d6ef60bba5420a1e11369afba485b15cd36c81ad982042e39b88
Methodv2026-11-18.2 · automated, not reviewed by a person
Correctionscorrections@patent.fyi